Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate

Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease. However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored the use of a monoclonal antibody–drug conjugate (trastuzumab–deruxtecan) in patients with disease they classify as HER2-“low.” Compared with “low” patients treated with one of several standard-of-care regimens, those receiving the conjugate therapy had greater median progression-free survival (roughly 10 months versus 5) and a longer overall survival (roughly 24 versus 18 months). Christine Sadlowski of the NEJM Group interviewed Dr. Modi during the Group’s coverage of this year’s ASCO meeting, where Modi presented her results. Have a listen. Modi et al. as published in the New England Journal of Medicine . The post Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate first appeared on Clinical Conversations .

You can listen to Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate online on Radio and Podcast. Open the player on this page to stream the available audio.

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate is an episode from Clinical Conversations » Podcast Feed by NEJM Group.

This episode is 11:24 long.

This episode was published on Jun 27, 2022.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Clinical Conversations » Podcast Feed when more episodes are available from the podcast feed.